1Department of Medical Science, Chonnam National University Graduate School, Gwangju, Korea
2Department of Thoracic and Cardiovascular Surgery, Chonnam National University, Chonnam National University Hospital Medical School, Gwangju, Korea
3Extracorporeal Circulation Research Team, Chonnam National University Hospital, Gwangju, Korea
4Department of Biomedical Sciences, Chonnam National University Graduate School, Chonnam National University Medical School, Gwangju, Korea
5Department of Pediatrics, Chonnam National University Children’s Hospital, Chonnam National University Medical School, Gwangju, Korea
Copyright © 2023 The Korean Society of Critical Care Medicine
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Study | Year | Species | ECC type | Duration of ECC (min) | Drainage catheter | Perfusion catheter | Priming volume (ml) | Purpose of study |
---|---|---|---|---|---|---|---|---|
Popovic et al. [14] | 1968 | Rat | VA/CPB | 70 | PE 200 tubing (ID: 1.4 mm) | PE 90 tubing (0.86 mm) | 13.7 | Model development |
Alexander et al. [15] | 1983 | Rat | VA/CPB | 360 | NA | NA | 8.7 | Device development |
Grocott et al. [16 | 2001 | Rat | VA/CPB | 60 | Dual-stage venous cannula (4.5 Fr) | Angiocatheter (20G) | 45 | Neuropathophysiology |
Dong et al. [17] | 2005 | Rat | VA/CPB | 60 | Angiocatheter (16G) | Angiocatheter (22G) | 16 | Model establishment |
Ordodi et al. [18] | 2008 | Rat | AA/CPB | 120 | Angiocatheter (24G) | Angiocatheter (24G) | 20 | Device development |
Huang et al. [19] | 2007 | Rat | VA/CPB | 60 | Angiocatheter (16G) | Angiocatheter (22G) | 10 | Pathophysiology |
Jungwirth et al. [20] | 2007 | Rat | VA/CPB | 90 | Dual-stage venous cannula (4.5 Fr) | Angiocatheter (20G) | 16 | Neuropathophysiology |
Qing et al. [21] | 2011 | Rat | VA/CPB | 90 | Dual-stage venous cannula (4.5 Fr) | Angiocatheter (20G) | 18 | Neuropathophysiology |
Waterbury et al. [22] | 2011 | Rat | VA/CPB | 80 | Angiocatheter (16G) | Angiocatheter (20G) | 12 | CPB and DHCA development |
Rungatscher et al. [12] | 2012 | Rat | VA/CPB | 90 | Angiocatheter (16G) | Angiocatheter (18G) | 10.5 | Pharmacology |
Mackensen et al. [23] | 2001 | Rat | VA/CPB | 150 | Angiocatheter (16G) | Angiocatheter (22G) | 10 | Model establishment |
Fujii et al. [24] | 2013 | Rat | VA/CPB | 60 | Angiocatheter (16G) | Polyethylene tubing (NA) | 15 | Pharmacology |
Fujii et al. [25] | 2013 | Rat | VA/CPB | 120 | Angiocatheter (16G) | Polyethylene tubing (NA) | 15 | CPB pathophysiology |
Ali et al. [1] | 2014 | Rat | VA/ECMO | 10 | Angiocatheter (20G) | Angiocatheter (24G) | 8 | Model establishment |
Luo et al. [2] | 2015 | Mouse | VA/ECC | 30 | Angiocatheter (24G) | Angiocatheter (24G) | 0.4 | ECC-induced SIRS |
Du et al. [26] | 2016 | Mouse | NA | NA | NA | NA | NA | ECMO treatment in pneumonia |
Chang et al. [7] | 2017 | Rat | VA/CPB, ECLS | 30 | Angiocatheter (14G) | Angiocatheter (20G) | 20 | CPB pathophysiology |
Bianchini et al. [10] | 2018 | Rat | VA/CPB | 60 | Angiocatheter (16G) | Angiocatheter (22G) | 10 | Pharmacology |
Madrahimov et al. [27] | 2018 | Mouse | VA/CPB | 90 | Polyurethane tube (2 Fr) | Angiocatheter (27G) | 0.85 | Model establishment |
Xie et al. [28] | 2012 | Rat | VA | 120 | Trocar (24G) | Trocar (24G) | NA | Platelet therapy with CPB |
Natanov et al. [29] | 2019 | Mouse | VV/ECMO | 240 | Double-lumen silicone catheter (2 Fr) | Double-lumen silicone-based catheter (2 Fr) | 0.5 | VV-ECMO induced pathophysiology |
Cho et al. [13] | 2021 | Rat | VA+VV/ECMO | 120 | Modified neonatal feeding tube (5 Fr) | Angiocatheter (24G) | 14 | Immunology |
Kayumov et al. [30] | 2022 | Rat | VA/ECMO | 120 | Modified neonatal feeding tube (5 Fr) | Angiocatheter (24G) | 14 | Septic shock, pressure-volume change |
ECMO research | |
---|---|
ECMO-related mechanics | LV unloading |
ECMO-related energetics | Effect of ECC on ATP production in mitochondria |
ECMO-related complications | Understand pathophysiology to prevent complications. |
Provide advanced care to patients that decrease life-threatening events. | |
Neuro-pathophysiology | Post-cardiac arrest ischemic brain injury in patients on ECMO or ECPR |
ECMO-related mechanical complications in the brain | |
The effect on the brain microcirculation | |
The effect on the neurologic performance | |
Development of ECMO devices | Hemocompatible and biocompatible ECMO devices |
Cause fewer mechanical complications. | |
Cause less vascular (endothelial) reaction. | |
Protect end-organs functions. | |
Adjunctive treatments in ECMO | Mesenchymal stem cells during ECMO |
Mechanical adjunctive treatment in ECMO | |
Pharmacodynamics and pharmacokinetics | The effects of the circuit/oxygenator/pump on various medications |
ECC: extracorporeal circulation; VA: veno-arterial; CPB: cardiopulmonary bypass; NA: not applicable; AA: arterio-arterial; DHCA: deep hypothermic circulatory arrest; ECMO: extracorporeal membrane oxygenation; SIRS: systemic inflammatory response syndrome; ECLS: extracorporeal life support; VV: veno-venous.
ECMO: extracorporeal membrane oxygenation; LV: left ventricle; ECC: extracorporeal circulation; ATP: adenosine triphosphate; ECPR: extracorporeal cardiopulmonary resuscitation.